Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference
February 28, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
February 24, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel...
Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022
February 22, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at B. Riley Virtual Oncology Conference
January 20, 2022 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
January 18, 2022 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference
January 03, 2022 16:45 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting
November 19, 2021 07:00 ET
|
Chimerix, Inc.
– Plenary Session Presentation on Saturday, November 20 – – Company to Host Conference Call at 8:30 a.m. ET on Monday, November 22 – DURHAM, N.C., Nov. 19, 2021 (GLOBE NEWSWIRE) --...
Chimerix to Present at Jefferies London Healthcare Conference
November 12, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
November 11, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update
November 04, 2021 07:05 ET
|
Chimerix, Inc.
– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma – –U.S. Food and Drug Administration (FDA) Published Article Summarizing Benefit-Risk Assessment of TEMBEXA for...